Indications for: ELITEK

Single course treatment for initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.

Adults and Children:

Give by IV infusion over 30 mins. 0.2mg/kg daily for 5 days. Dosing >5 days or more than one course of treatment: not recommended.

ELITEK Contraindications:

History of anaphylaxis, or development of hemolytic reactions or methemoglobinemia to rasburicase. G6PD deficiency.

Boxed Warning:

Anaphylaxis. Hemolysis. Methemoglobinemia. Interference with uric acid measurements.

ELITEK Warnings/Precautions:

Discontinue permanently if serious hypersensitivity reactions (including anaphylaxis), hemolysis, or methemoglobinemia develops. Screen high risk patients (eg, African or Mediterranean ancestry) for G6PD deficiency prior to initiation. Pregnancy. Nursing mothers: not recommended (during and for 2 weeks after the last dose).

ELITEK Classification:

Urate oxidase.

ELITEK Interactions:

Interferes with uric acid measurements in blood samples left at room temperature.

Adverse Reactions:

GI upset, pyrexia, peripheral edema, anxiety, headache, abdominal pain, constipation, hypophosphatemia, hyperbilirubinemia, mucositis, sepsis; anaphylaxis, hemolysis, methemoglobinemia.

Generic Drug Availability:


How Supplied:

Single-dose vials 1.5mg—3 (w. diluent); 7.5mg—1 (w. diluent)